This book provides information about different types and stages of cancer and their subtypes with their respective molecular mechanisms, etiology, histopathology, and cellular origins. This book also provides detailed information about cancer incidence, mortality, and different types of technologies both bio and nano employed in cancer diagnosis and screening, and their applications in cancer therapies. This book informs readers about molecular mechanisms of cancer, diagnosis, and therapies along with different computational techniques used on a single platform. The chapters include a broad and integrated perspective on cancer-related topics. This book covers both conventional and emerging techniques employed in cancer screening and diagnosis, including imaging, biomarker, and electrochemical nanosensor-based approaches with detailed information on sensor development. Similarly, this book also covers the mechanisms of different conventional and emerging herbal and nano therapies used in cancer treatment. The authors discuss applications of different computational and mathematical tools, such as machine-learning methods, that can be employed in cancer diagnosis and therapy at the level of personalized medicine. Features: Offers an integrated approach to provide information about all aspects of cancer biology, diagnosis, and therapy Focuses on both conventional and emerging tools/techniques applicable in cancer screening and diagnosis Covers the mechanisms of conventional and emerging anticancer drugs and therapies Provides insights about a personalized medicine-based approach in cancer diagnosis and therapy This book is essential for university students, course lecturers, researchers, and industrialists working in the fields of cancer biology, medicine, and pharmacology.

Cancer continues to be one of the major causes of death throughout the developed world, which has led to increased research on effective treatments. Because of this, in the past decade, rapid progress in the field of cancer treatment has been seen. Recent Advances in Cancer Research and Therapy reviews in specific details some of the most effective and promising treatments developed in research centers worldwide. While referencing advances in traditional therapies and treatments such as chemotherapy, this book also highlights advances in biotherapy including research using Interferon and Super Interferon, HecI based and liposome based therapy, gene therapy, and p53 based cancer therapy. There is also a discussion of current cancer research in China including traditional Chinese medicine. Written by leading scientists in the field, this book provides an essential insight into the current state of cancer therapy and treatment. - Includes a wide range of research areas including a focus on biotherapy and the development of novel cancer therapeutic strategies. - Formatted for a broad audience including all working in researching cancer treatments and therapies. - Discusses special traits and results of Chinese cancer research.

Early diagnosis of cancer and other non-oncological disorders gives a significant advantage for curing the disease and improving patient's life expectancy. Recent advances in biosensor-based techniques which are designed for specific biomarkers can be exploited for early diagnosis of diseases. Biosensor Based Advanced Cancer Diagnostics covers all available biosensor-based approaches and comprehensive technologies; along with their application in diagnosis, prognosis and therapeutic management of various oncological disorders. Besides this, current challenges and future aspects of these diagnostic approaches have also been discussed. This book offers a view of recent advances and is also helpful for designing new biosensor-based technologies in the field of medical science, engineering and biomedical technology. Biosensor Based Advanced Cancer Diagnostics helps biomedical engineers, researchers, molecular biologists, oncologists and clinicians with the development of point of care devices for disease diagnostics and prognostics. It also provides information on developing user friendly, sensitive, stable, accurate, low cost and minimally invasive modalities which can be adopted from lab to clinics. This book covers in-depth knowledge of disease biomarkers that can be exploited for designing and development of a range of biosensors. The editors have summarized the potential cancer biomarkers and methodology for their detection, plus transferring the developed system to clinical application by miniaturization and required integration with microfluidic systems. - Covers design and development of advanced platforms for rapid diagnosis of cancerous biomarkers - Takes a multidisciplinary approach to sensitive transducers development, nano-enabled advanced imaging, miniaturized analytical systems, and device packaging for point-of-care applications - Offers an insight into how to develop cost-effective diagnostics for early detection of cancer

This work covers the pathophysiology of cancer, exploring the difficulty of optimal treatment due to the complexity and diversity of cancer types. The search for distinctive molecular biology characteristics of tumor cells is especially relevant in the identification of overexpressed receptors and proteins that can be used as a target for cancer treatment. We highlight the main therapeutic modalities, particularly conventional systemic chemotherapy, addressing its mechanisms of action, therapeutic classes and even the toxic effects. We also describe the main tumor markers, their importance in the diagnosis and treatment of cancer, and the specificity of tumor cells. The first chapters serve as an introduction to the central topic of this book, targeted therapy. Key aspects of target therapy, such as classes of drugs, immunotherapy, monoclonal antibodies, checkpoint inhibitors, cancer vaccines and tyrosine kinase inhibitors are presented, and, for each one, the benefits, as well as the adverse effects are reported. Chapter 6 compares conventional systemic chemotherapy and targeted therapy, identifies the risks and benefits and also the eligibility criteria for patient care. The possibility of targeted therapy replacing conventional chemotherapy is discussed while reviewing studies that demonstrate the benefits of combining both types of treatment. Finally, the introduction of pharmaceutical nanotechnology to improve antineoplastic agents is addressed in the last chapter and sets the direction for future research in cancer treatment. This is a valuable resource for many health professionals including physicians, pharmacists, nurses, researchers and students interested in the field of oncology.

Advances in Cancer Research, Volume 150, the latest release in this ongoing series, covers the relationship(s) between autophagy and senescence, how they are defined, and the influence of these cellular responses on tumor dormancy and disease recurrence. Specific sections in this new release include Autophagy and senescence, converging roles in pathophysiology, Cellular senescence and tumor promotion: role of the unfolded protein response, autophagy and senescence in cancer stem cells, Targeting the stress support network regulated by autophagy and senescence for cancer treatment, Autophagy and PTEN in DNA damage-induced senescence, mTOR as a senescence manipulation target: A forked road, and more. - Addresses the relationship between autophagy and senescence in cancer therapy - Covers autophagy and senescence in tumor dormancy - Explores autophagy and senescence in disease recurrence

Advanced Drug Delivery Systems in the Management of Cancer discusses recent developments in nanomedicine and nano-based drug delivery systems used in the treatment of cancers affecting the blood, lungs, brain, and kidneys. The research presented in this book includes international collaborations in the area of novel drug delivery for the treatment of cancer. Cancer therapy remains one of the greatest challenges in modern medicine, as successful treatment requires the elimination of malignant cells that are closely related to normal cells within the body. Advanced drug delivery systems are carriers for a wide range of pharmacotherapies used in many applications, including cancer treatment. The use of such carrier systems in cancer treatment is growing rapidly as they help overcome the limitations associated with conventional drug delivery systems. Some of the conventional limitations that these advanced drug delivery systems help overcome include nonspecific targeting, systemic toxicity, poor oral bioavailability, reduced efficacy, and low therapeutic index. This book begins with a brief introduction to cancer biology. This is followed by an overview of the current landscape in pharmacotherapy for the cancer management. The need for advanced drug delivery systems in oncology and cancer treatment is established, and the systems that can be used for several specific cancers are discussed. Several chapters of the book are devoted to discussing the latest technologies and advances in nanotechnology. These include practical solutions on how to design a more effective nanocarrier for the drugs used in cancer therapeutics. Each chapter is written with the goal of informing readers about the latest advancements in drug delivery system technologies while reinforcing understanding through various detailed tables, figures, and illustrations. Advanced Drug Delivery Systems in the Management of Cancer is a valuable resource for anyone working in the fields of cancer biology and drug delivery, whether in academia, research, or industry. The book will be especially useful for researchers in drug formulation and drug delivery as well as for biological and translational researchers working in the field of cancer. - Presents an overview of the recent perspectives and challenges within the management and diagnosis of cancer - Provides insights into how advanced drug delivery systems can effectively be used in the management of a wide range of cancers - Includes up-to-date information on diagnostic methods and treatment strategies using controlled drug delivery systems

This work has been selected by scholars as being culturally important, and is part of the knowledge base of civilization as we know it. This work was reproduced from the original artifact, and remains as true to the original work as possible. Therefore, you will see the original copyright references, library stamps (as most of these works have been housed in our most important libraries around the world), and other notations in the work. This work is in the public domain in the United States of America, and possibly other nations. Within the United States, you may freely copy and distribute this work, as no entity (individual or corporate) has a copyright on the body of the work. As a reproduction of a historical artifact, this work may contain missing or blurred pages, poor pictures, errant marks, etc. Scholars believe, and we concur, that this work is important enough to be preserved, reproduced, and made generally available to the public. We appreciate your support of the preservation process, and thank you for being an important part of keeping this knowledge alive and relevant.

At present there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes. Intriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simply monitored in their course by a periodic blood sample, but sometimes this monitoring shows dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarker does not entirely know their limits and the total potential applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and "polluted" knowledge may have dramatic consequences for patient. The aim of this book is to diffuse all aspects of cancer biomarkers, from their biochemical peculiarities to all clinical implications by passing through their physiology and pathophysiology. This critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time facilitating the research of new and more sensitive-specific signals of the cancer cell proliferation.

Diagnostic and Therapeutic Applications of Exosomes in Cancer evaluates the potential of exosome content manipulation in the development of novel therapeutics. In recent years, exosomes, the small vesicles produced by all cell types, have been identified as contributors to cancer growth and metastasis. However, due to their unique biophysical properties, they are also being tested for use in therapeutic design and delivery, as well as in diagnostics. This book presents a comprehensive analysis on exosomes, with a main emphasis on their biogenesis and signaling, use as biomarkers, and as tools for imaging, drug delivery and the treatment of cancer. - Covers emerging pharmaceutical and diagnostic applications, including exosomes being tested as carriers of anticancer drugs, ongoing clinical trials, and exosomes as imaging agents for cancer diagnosis and treatment - Brings together a team of highly regarded international authors who provide a full-rounded analysis - Presents comprehensive coverage of the unique biophysical properties of exosomes - Explores current and future possibilities

There are more than 100 types of cancers In Part II, head and neck cancer is d- affecting all parts of the human body. cussed. The global number of annual new More than 11 million people are diagnosed cases of this malignancy is ~500,000. These with cancer every year, and it is estimated malignancies include oral squamous cell that there will be 16 million new cases by carcinoma, salivary gland tumors, tons- the year 2020. In 2005, 7. 6 million peo- lar cancer, tongue cancer, nasopharyngeal ple died of cancer, that is, 13% of the 58 carcinoma, and retinoblastoma, which are million deaths worldwide. It is estimated detailed. In Part III, diagnosis, therapy, and that 9 million people will die from can- prognosis of thyroid carcinoma are d- cer worldwide in 2015 and 11. 4 million cussed. The global number of new cases of will die in 2030. More than 70% of all thyroid cancer is ~141,000, and the number cancer deaths occur in low and middle of worldwide thyroid mortalities is ~35,375. income countries. These statistics underlie The number of new cases of this cancer in the fact that cancer is the deadliest of all the United States is ~33,550. Molecular human diseases. The enormity of the glo- genetics of thyroid cancer, gene expr- bal healthcare costs as a result of cancer sion markers for diagnosis, papillary t- cannot be overemphasized.